NASDAQ:RGLS
Regulus Therapeutics Inc. Stock News
$2.22
-0.120 (-5.13%)
At Close: Apr 18, 2024
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
01:11pm, Wednesday, 13'th Mar 2024
Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
08:00am, Wednesday, 22'nd Nov 2023
SAN DIEGO , Nov. 22, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (
Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance
12:06pm, Wednesday, 23'rd Aug 2023
Long-established in the Biotechnology industry, Regulus Therapeutics Inc ( RGLS , Financial) has enjoyed a stellar reputation. It has recently witnessed a surge of 13.27%, juxtaposed with a three-mont
Regulus (RGLS) Surges on Enrollment Completion for RGLS8429
02:25pm, Friday, 14'th Apr 2023
Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.
Regulus Therapeutics, Inc. (RGLS) Q3 2022 Earnings Call Transcript
09:49pm, Thursday, 10'th Nov 2022
Regulus Therapeutics, Inc. (NASDAQ:RGLS ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Crispina Calsada - CFO Jay Hagan - President, CEO & Director Denis Drygin -
Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study
01:32pm, Tuesday, 13'th Sep 2022
Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.
Hot Penny Stocks to Know About Right Now? 3 to Watch
06:00am, Tuesday, 13'th Sep 2022
Here's what you need to know about trading penny stocks on September 13th The post Hot Penny Stocks to Know About Right Now? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Informa
Regulus Therapeutics to Participate in Upcoming Investor Conferences
04:05pm, Friday, 02'nd Sep 2022
SAN DIEGO , Sept. 2, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (th
Regulus Therapeutics, Inc. (RGLS) CEO Joseph Hagan on Q2 2022 Results - Earnings Call Transcript
06:51pm, Thursday, 11'th Aug 2022
Regulus Therapeutics, Inc. (NASDAQ:RGLS ) Q2 2022 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Crispina Calsada - CFO Joseph Hagan - President & CEO Conference Call Partici
Top Penny Stocks to Buy Now? 3 to Watch in June 2022
05:04pm, Friday, 27'th May 2022
Can these penny stocks make gains next month? The post Top Penny Stocks to Buy Now?
Check These 3 Penny Stocks Out For Your Watchlist
07:35pm, Monday, 23'rd May 2022
Are these penny stocks on your watchlist right now? The post Check These 3 Penny Stocks Out For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
04:30pm, Tuesday, 17'th May 2022
SAN DIEGO , May 17, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (th
7 Penny Stocks With 10x Potential This Year
07:00am, Tuesday, 17'th May 2022
These penny stocks all have 10x potential or greater during the remainder of 2022. They are risky but relatively straightforward.
How to Trade Penny Stocks When the Stock Market Crashes
10:13pm, Sunday, 15'th May 2022
Here are three tips for trading penny stocks during a bear market The post How to Trade Penny Stocks When the Stock Market Crashes appeared first on Penny Stocks to Buy, Picks, News and Information |
Regulus Therapeutics, Inc. (RGLS) CEO Joseph Hagan on Q1 2022 Results - Earnings Call Transcript
08:52pm, Thursday, 12'th May 2022
Regulus Therapeutics, Inc. (NASDAQ:RGLS ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Crispina Calsada - CFO Joseph Hagan - President, CEO & Director Conference Call
